ProQR Therapeutics N.V.
PRQR · Pharmaceutical Preparations · EDGAR filings ↗
Grade
D48Early clinical-stage RNA-editing platform, funded for ~7 quarters with Lilly partnership validation.
Strengths
- ~$109M cash, ~6.9-quarter runway (53rd pct), low leverage and current ratio 3.1
- Lilly collaboration (up to 10 targets) validates the Axiomer platform
Risks
- Pre-revenue with deep losses (ROE -0.85, ROIC -0.63) and lead asset only in Phase 1
- No pivotal data; long path to approval and ongoing dilution risk
Notable findings
- No interest coverageInterest coverage -46.77 (cannot cover interest)
- RestatementIn December 2022, the Company issued 9,381,586 shares to Lilly pursuant to the amended and restated licensing and research collaboration between the Company and Lilly, resulting in gross proceeds of € 8-K ↗
- Net lossNet loss (net margin -265.2%)
- Cash burnNegative free cash flow (-63.2M)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-273.1%
Net margin
-265.2%
Return on equity
-85.4%
Return on assets
-37.4%
ROIC
-63.3%
Revenue growth (QoQ)
62.8%
Debt / equity
0.1×
Interest coverage
-46.8×
Current ratio
3.1×
Free cash flow
-$63M
Tangible book value
$58M
Cash & investments
$109M
Cash runway
7q
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-03-12 | 2025-12-31 | 0001104659-26-026713 ↗ |
| 20-F | 2025-03-13 | 2024-12-31 | 0001558370-25-002851 ↗ |
| 20-F | 2024-03-13 | 2023-12-31 | 0001558370-24-003060 ↗ |
| 20-F | 2023-03-29 | 2022-12-31 | 0001558370-23-004917 ↗ |
| 20-F | 2022-04-29 | 2021-12-31 | 0001558370-22-006395 ↗ |
| 20-F | 2021-03-24 | 2020-12-31 | 0001558370-21-003399 ↗ |
| 20-F | 2020-03-31 | 2019-12-31 | 0001558370-20-003457 ↗ |
| 20-F | 2019-03-28 | 2018-12-31 | 0001558370-19-002525 ↗ |
| 20-F | 2018-03-30 | 2017-12-31 | 0001558370-18-002577 ↗ |
| 20-F | 2017-03-31 | 2016-12-31 | 0001193125-17-106844 ↗ |
| 20-F | 2016-03-31 | 2015-12-31 | 0001193125-16-525912 ↗ |
| 20-F | 2015-04-22 | 2014-12-31 | 0001193125-15-142091 ↗ |